Literature DB >> 8499674

A comparative study of three ovulation induction protocols in polycystic ovarian disease patients in an in vitro fertilization/embryo transfer program.

N O Turhan1, P G Artini, G D'Ambrogio, F Droghini, C Battaglia, A D Genazzani, A Volpe, A R Genazzani.   

Abstract

PURPOSE: This study compares the results of three ovulation induction protocols in polycystic ovarian disease (PCOD) patients undergoing an in vitro fertilization-embryo transfer (IVF-ET) program. A total of 85 cycles was studied. The patients were treated with clomiphene citrate (CC) plus human menopausal gonadotropin (hMG) (CC/hMG group), with purified menofollitropin (pFSH) plus hMG (pFSH/hMG group), and with pFSH/hMG plus gonadotropin releasing hormone analogue (GnRH-a) (analogue group). In the analogue group the suppression of luteinizing hormone (LH) with GnRH-a decreased the number of follicles < 12 mm on the day of human chorionic gonadotropin (hCG) administration and the number and percentage of immature oocytes retrieved and increased the percentage of mature oocytes retrieved.
RESULTS: However, fertilization rates of oocytes, cleaved embryo rates, pregnancy rates following replacement, and pregnancy outcomes were not different.
CONCLUSION: Although the suppression of the hypothalamic-pituitary-ovarian axis with GnRH-a in PCOD patients improved follicular synchrony and oocyte maturity, none of the ovulation induction protocols was superior to the others with respect to pregnancy rates and pregnancy outcomes.

Entities:  

Mesh:

Year:  1993        PMID: 8499674     DOI: 10.1007/BF01204435

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  26 in total

1.  Ovarian sensitivity to gonadotrophins in patients with PCO is unaffected by suppression of LH.

Authors:  R Fleming; M P Hamilton; C Conaghan; W P Black; J R Coutts
Journal:  Clin Endocrinol (Oxf)       Date:  1990-01       Impact factor: 3.478

2.  Cumulative conception rates following gonadotropin therapy.

Authors:  J Dor; D J Itzkowic; S Mashiach; B Lunenfeld; D M Serr
Journal:  Am J Obstet Gynecol       Date:  1980-01-01       Impact factor: 8.661

3.  Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone.

Authors:  J Adams; S Franks; D W Polson; H D Mason; N Abdulwahid; M Tucker; D V Morris; J Price; H S Jacobs
Journal:  Lancet       Date:  1985 Dec 21-28       Impact factor: 79.321

4.  Leuprolide acetate: serum and follicular fluid concentrations and effects on human fertilization, embryo growth, and granulosa-lutein cell progesterone accumulation in vitro.

Authors:  W C Dodson; T Myers; P C Morton; P M Conn
Journal:  Fertil Steril       Date:  1988-10       Impact factor: 7.329

5.  Pituitary-ovarian relationships in polycystic ovary syndrome.

Authors:  D T Baird; C S Corker; D W Davidson; W M Hunter; E A Michie; P F Van Look
Journal:  J Clin Endocrinol Metab       Date:  1977-10       Impact factor: 5.958

6.  Pulsatile luteinizing hormone-releasing hormone therapy in women with polycystic ovary syndrome.

Authors:  A Eshel; N A Abdulwahid; N A Armar; J M Adams; H S Jacobs
Journal:  Fertil Steril       Date:  1988-06       Impact factor: 7.329

7.  Reduced in-vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase.

Authors:  J D Stanger; J L Yovich
Journal:  Br J Obstet Gynaecol       Date:  1985-04

8.  A new systematic treatment for infertile women with abnormal hormone profiles.

Authors:  R Fleming; A H Adam; D H Barlow; W P Black; M C MacNaughton; J R Coutts
Journal:  Br J Obstet Gynaecol       Date:  1982-01

9.  Influence of different stimulation treatments on oocyte characteristics and in-vitro fertilizing ability.

Authors:  J Testart; J Belaisch-Allart; R Forman; A Gazengel; N Strubb; A Hazout; R Frydman
Journal:  Hum Reprod       Date:  1989-02       Impact factor: 6.918

10.  Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.

Authors:  M Filicori; E Campaniello; L Michelacci; A Pareschi; P Ferrari; G Bolelli; C Flamigni
Journal:  J Clin Endocrinol Metab       Date:  1988-02       Impact factor: 5.958

View more
  4 in total

Review 1.  Clinical utility of adjuvant growth hormone in the treatment of patients with polycystic ovaries undergoing in vitro fertilization.

Authors:  P G Artini; A A de Micheroux; F Taponeco; V Cela; G D'Ambrogio; A R Genazzani
Journal:  J Assist Reprod Genet       Date:  1997-01       Impact factor: 3.412

Review 2.  The significance of high follicular-phase luteinizing hormone levels in the treatment of women with polycystic ovarian syndrome by in vitro fertilization.

Authors:  B C Tarlatzis; G Grimbizis
Journal:  J Assist Reprod Genet       Date:  1997-01       Impact factor: 3.412

3.  Do basal Luteinizing Hormone and Luteinizing Hormone/Follicle-Stimulating Hormone Ratio Have Significance in Prognosticating the Outcome of In vitro Fertilization Cycles in Polycystic Ovary Syndrome?

Authors:  Neeta Singh; Neha Mishra; Yogita Dogra
Journal:  J Hum Reprod Sci       Date:  2021-03-30

4.  Adverse Effects of Polycystic Ovarian Syndrome on Pregnancy Outcomes in Women With Frozen-Thawed Embryo Transfer: Propensity Score-Matched Study.

Authors:  Zhexin Ni; Shanshan Mei; Siting You; Yi Lin; Wen Cheng; Ling Zhou; Yanping Kuang; Chaoqin Yu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-06       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.